- Home
- HCKT vs ANAB Comparison
HCKT vs ANAB Comparison
Compare HCKT & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCKT
- ANAB
- Stock Information
- Founded
- HCKT 1991
- ANAB 2005
- Country
- HCKT United States
- ANAB United States
- Employees
- HCKT N/A
- ANAB N/A
- Industry
- HCKT Professional Services
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- HCKT Consumer Discretionary
- ANAB Health Care
- Exchange
- HCKT Nasdaq
- ANAB Nasdaq
- Market Cap
- HCKT 636.1M
- ANAB 621.1M
- IPO Year
- HCKT 1998
- ANAB 2017
- Fundamental
- Price
- HCKT $21.09
- ANAB $20.22
- Analyst Decision
- HCKT Strong Buy
- ANAB Buy
- Analyst Count
- HCKT 3
- ANAB 10
- Target Price
- HCKT $29.67
- ANAB $48.00
- AVG Volume (30 Days)
- HCKT 361.4K
- ANAB 459.5K
- Earning Date
- HCKT 08-05-2025
- ANAB 08-06-2025
- Dividend Yield
- HCKT 2.32%
- ANAB N/A
- EPS Growth
- HCKT N/A
- ANAB N/A
- EPS
- HCKT 0.59
- ANAB N/A
- Revenue
- HCKT $309,265,000.00
- ANAB $123,164,000.00
- Revenue This Year
- HCKT $6.06
- ANAB N/A
- Revenue Next Year
- HCKT $5.46
- ANAB $24.39
- P/E Ratio
- HCKT $35.01
- ANAB N/A
- Revenue Growth
- HCKT 3.98
- ANAB 304.17
- 52 Week Low
- HCKT $19.39
- ANAB $12.21
- 52 Week High
- HCKT $34.02
- ANAB $40.70
- Technical
- Relative Strength Index (RSI)
- HCKT 42.97
- ANAB 34.66
- Support Level
- HCKT $19.93
- ANAB $19.48
- Resistance Level
- HCKT $20.82
- ANAB $20.35
- Average True Range (ATR)
- HCKT 0.72
- ANAB 1.27
- MACD
- HCKT 0.03
- ANAB -0.13
- Stochastic Oscillator
- HCKT 43.70
- ANAB 18.49
About HCKT Hackett Group Inc (The).
The Hackett Group Inc is an IP platform-based Generative Artificial Intelligence (Gen AI) strategic consulting and executive advisory digital transformation firm. The Hackett Group provides dedicated expertise in Gen AI-enabled enterprise transformation services across the front, mid and back office areas, including its highly recognized Oracle, SAP, OneStream and Coupa implementation offerings. It operates in three segments Oracle Solutions, SAP Solutions, and Global S&BT. It generates the majority of its revenue from the Global S&BT segment in the United States.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).